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ObjectiveaaThe objective of this epidemiological study was to evaluate the current treatment status as well as the acceptance of medication 
and satisfaction with life in outpatients with bipolar disorder in Germany.
MethodsaaData for this cross-sectional epidemiologic survey was collected between February 15th, 2006 and May 31st, 2006. Three 
hundreds six bipolar euthymic outpatients under routine treatment conditions were included in the study. Forty one practicing psychia-
trists used a clinical interview to evaluate the current treatment status, acceptance of current medication, and current life satisfaction. 
ResultsaaThe majority of patients suffered from “pure” bipolar-II-disorder (50.6%), followed by 23.0% with “pure” bipolar-I-disorder. 
Apart from these patients, 12.9% of all participants had a history of mixed episodes and 5.6% a history of rapid cycling. Mean duration 
of bipolar disorder was 10.6 years. The majority of patients (54.3%) received psychopharmacological monotherapy. Combination thera-
py was administered in 45.9% of the patients, 39.3% receiving two agents, and 6.6% three agents. Antidepressants (64.1%) were the most 
common combination medications. Monotherapy was used preferably in bipolar-I- (62.7%) and bipolar-II-disorders (56.2%), combina-
tion therapy predominantly in patients with a history of mixed episodes (57.7%) and rapid cycling (55.0%). Half of the patients (49.2%) 
were able to hold an occupation. 84.2% of all patients were satisfied with their medication. Overall, patients evaluated their life satisfac-
tion between “good” and “satisfactory” (2.69 according to German school grades where 1 is the highest and 6 the lowest mark). Patients 
receiving lithium, valproate or antidepressants as monotherapy rated above the mean, patients with combination therapy, carbamazepine 
monotherapy or medications summarized as “others” rated below the mean.
ConclusionaaMost of the German outpatients received a pharmacotherapy that is recommended in the guidelines of bipolar disorder. The 
use of (atypical) antipsychotics was low. Conversely, the incidence of treatment with tricyclic antidepressants (not guideline compatible), 
was observed to be relatively high. Irrespective of their medication, in Germany patients with bipolar disorder show a high acceptance of 
their pharmacotherapy, and rate their life satisfaction as high. Nonetheless, half of the evaluated patients were not able to pursue a profes-
sion. Besides the disease age, gender and family life e.g., child care may also play a confounding role regarding the unemployment statistics.
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INTRODUCTION
Bipolar disorder is a serious disease with a lifetime preva-
lence of 0.8-1.5% for bipolar I disorder and up to 5% for the 
whole bipolar spectrum.
1 Risk of death due to suicide is esti-
mated to be approximately 20 times higher than that of the gen-
eral population
2 and, despite therapeutic efforts, the risk of a 
chronic course is relatively high. About 75% of the patients 
have a recurrent episode within five years.
3 Bipolar patients 
have been estimated to spend approximately half of their life-
time being ill.
4 The burden of disease is high, mainly in conse-
quence of depressive episodes and symptoms. Depressive epi-
sodes last longer than the manic ones, they are harder to treat 
and cause patients to suffer more.
1 The depression/mania ra-
tio during the course of the disease is up to about 3 : 1.
4 Thus, 
bipolar patients suffer nearly half of their life (being ill) from 
bipolar symptoms, about three quarters of the time in conse-
quence of depressive episodes and symptoms.
5 
Bipolar disorder has also serious socio-economic effects: 
according to the World Health Organization report (2000), bi-
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polar disorder is the tenth leading cause of disability.
6 
Concerning pharmacological treatment, there are several 
guidelines for bipolar disorder that recommend a monother-
apy with mood stabilizers or atypical antipsychotics as the 
first line treatment. In cases of rapid cycling, mixed episodes, 
or severe manic episodes a combination therapy is recom-
mended. The use of tricyclic antidepressants (TCA) or a mono-
therapy with antidepressants should be avoided because of 
the high “switching risk”.
7,8 
Incomplete control of bipolar disorder morbidity with mo-
notherapeutic strategies has encouraged applications of vari-
ous combinations of mood-stabilizing and other psychotro-
pic agents in an effort to provide better symptomatic control.
9 
A combination therapy, especially in patients with manic epi-
sodes is nowadays routinely carried out in clinical practice: 90% 
of hospitalized manic inpatients are treated with a combina-
tion of a mood stabilizers and antipsychotic agents. Over the 
years, the significance of combination therapies has grown: 
between 1980 and 1984 about 10% and between 1990 and 1994 
about 45% of bipolar patients were treated with a combination 
of at least two medications.
10 A combination therapy has also 
become more frequent in depressive episodes: Adding anti-
depressants to a mood stabilizer has increasingly become clini-
cal practice in the treatment of moderate to severe depressive 
episodes, despite the inconsistent data for the use of antide-
pressants in these cases .
11,12 Moreover, combination therapy is 
often accompanied by more side effects which can be expect-
ed to affect the adherence to the recommended treatment neg-
atively.
13 The rate of partial or total nonadherence to mood sta-
bilizers is approximately 51% for monotherapies with the com-
mon mood stabilizers (lithium, carbamazepine and valproate)
14 
and 48% for antipsychotics.
15 There is only a very limited num-
ber of studies examining the effectiveness, as well as the safe-
ty and tolerability of combination therapies.
16,17 
Improvements in the quality of care in bipolar patients in 
the United States (US) were reported in a retrospective study 
comprising the years 1991-1999. The number of monothera-
pies with mood stabilizers had increased whereas monother-
apies with antidepressants had decreased (which conforms with 
the guidelines).
18 
There are several factors complicating the treatment of bi-
polar disorder such as the adherence to treatment and a lack 
of life satisfaction or the life satisfaction issues. In general, 
risk factors for medication nonadherence include younger 
age, minoritiy ethnicity, limited family support, and a range 
of comorbidities, in particular substance abuse and personal-
ity disorders.
15 Nonadherence predicts a less favourable course 
of treatment in terms of longer durations of hospitalization, 
higher likelihood of treatment switch or augmentation, high-
er inpatient charges, and higher rates of compulsory treat-
ment.
19,20 Unfortunatelly, long-term adherence to prescribed tr-
eatment is difficult to sustain in bipolar patients, especially dur-
ing periods of euthymia or manic episodes. 
In an epidemiologic study it was shown, that adherence is ac-
companied by higher life satisfaction: in comparison to non-
adherent participants, adherent patients had fewer health prob-
lems and more resources for coping with stress. In addition 
to that, they also possessed a stronger belief that their own be-
haviors controlled their health status.
21 
With respect to the quality of life (QOL), outpatients with bi-
polar disorder have reported a significantly lower QOL com-
pared to the general population. The number of symptoms 
correlated consistently negatively with QOL.
22 Adverse effects 
of medication are also negatively associated with QOL on the 
physical and environment domains.
23 To our knowledge, there 
are no comparison studies investigating differences in life sat-
isfaction subject to different medications. However, it is known 
that the use of atypical antipsychotics is not associated with 
QOL, but subjects with bipolar disorder receiving olanzapine 
perceived better psychological QOL than those receiving ris-
peridone and better psychological and social relationship 
QOL than those receiving no atypical antipsychotic. Despite 
reports about a lack of association between atypical antipsy-
chotics and QOL variables, there is also evidence that bipolar 
patients receiving olanzapine perceive their QOL as higher com-
pared to patients treated with risperidone. Furthermore they 
perceived themselves as having qualitatively better psychologi-
cal and social relationships compared to patients who received 
no atypical antipsychotic medication.
23 At present, there is a 
lack of data concerning patients’ current medication status and 
the acceptance of prescribed pharmacotherapy in naturalisti-
cally treated bipolar outpatients in Germany.
The objective of this naturalistic and epidemiologic study 
was to assess the current medication status (such as monother-
apy versus combination therapy) in bipolar patients, in partic-
ular with regard to the type of bipolar disorder (bipolar I or II) 
and type of episode (with or without a history of mixed epi-
sodes and rapid cycling). Moreover, acceptance of current ph-
armacotherapy and life satisfaction was assessed in relation 
to the current medication status. 
METHODS
Patients with bipolar disorder were diagnosed according to 
the International Classification of Diseases, 10th Revision 
(ICD-10) criteria and clinical interviews by the attending psy-
chiatrists. 
The cross-sectional epidemiologic survey was conducted 
between February, 1st 2006 and May, 31st 2006 in Germany. 
The study was carried out by 41 voluntary participating psy-A Quante et al. 
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chiatrists in private practice, who were located in all parts of 
Germany, allowing an-approximately-representative estima-
tion of the German patient population. The psychiatrists were 
informed about the survey and methods by letter and had the 
possibility to decide whether they want to participate or not. 
Three hundreds six outpatients with euthymic bipolar disor-
der were included, since they routinely came to the participat-
ing doctor during February, 1st 2006 and May, 31st 2006.
A case report form, prepared by cooperating psychiatrists, 
with the following parameters was developed and used:
-demographic data of patients, including birthday and sex
-history of medical treatment
-classification of bipolar disorder (“pure” bipolar-I or -II-dis-
order: defined as patients without mixed episodes or rapid cy-
cling in their histories, versus patients with bipolar-I and -II-
disorder with a history of mixed episodes or rapid cycling)
-years of illness, illness symptoms and severity
-treatment status: current medication with dosage and du-
ration of treatment
-acceptance of medication: we used a scale with the follow-
ing 4 items: 1=very good, 2=good, 3=bad or 4=no acceptance
-hospitalizations in the last 24 months
-occupational status including the working time 
-life satisfaction: a scale with 6 numeric items according to 
the German school grade systematics, in which lower num-
bers depict higher satisfaction (1=very good, 2=good, 3=sat-
isfactory, 4=fair, 5=poor, 6=unsatisfying) was used. 
Statistical analyses
Statistical analyses employed commercial software (SPSS® 
15.0 for windows). 
Statistical analysis was preceded by a detailed plan. Data in-
put was single data entry, but tests of plausibility were carried 
out and data was corrected if applicable. Since it was a cross-
sectional epidemiologic survey, statistical analyses was planned 
and performed in a descriptive character, therefore no sam-
ple size justification was done. Descriptive methods were used 
to analyze the data. The usual parameters were calculated for 
continuous data (number n, mean, standard deviation, mini-
mum, maximum). Qualitative data was described by means 
of absolute and relative frequencies. “Valid” percentages refer 
only to valid data, missing data were disregarded. If not oth-
erwise stated, results were always presented for the entire study 
cohort. Types of medication were analyzed separately for the 
respective subgroups. Analyses of hospitalization and occupa-
tional status were performed for each medication subgroup 
separately. Additionally, subgroups concerning the individual 
mono- and combination therapies were created for the anal-
yses of compliance and life satisfaction. 
RESULTS
Demographic data
Altogether 356 outpatients from Germany participated in 
this survey. One hundred two (53.9%) were female and 161 
(45.2%) male. The mean age was 47.5 years (18-85 years). Most 
of the patients were between 40 and 59 years (53.6%). The mean 
duration of illness was 10.6 years (median 8 years) Figure 1.
Type of bipolar disorder
The current clinical status of all patients was euthymic. In-
terestingly, the majority of patients suffered from “pure” bipo-
lar-II-disorder (n=177; 50.6%), followed by 80 patients (23.0%) 
with “pure” bipolar-I-disorder. Apart from these patients, 45 
(12.9%) of all participants had a history of mixed episodes and 
20 (5.6%) a history of rapid cycling. In 7.9% (n=28) of cases 
data were missing or disorder was classified as “others”.
Current treatment status
Antidepressants were the type of medication most com-
monly used (24.3%), followed by lithium (21.7%), valproate 
(20.2%) and carbamazepine (12.0%). The most frequently 
applied antidepressants were serotonin-reuptake-inhibitors 
(SSRI) with 51.3%, followed by TCA with 25.2%.
The majority of patients (n=190; 54.3%) were treated with 
one medication (monotherapy). Concerning monotherapy, the 
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most frequently administered medication was valproate (27.9%), 
followed by lithium (27.5%), carbamazepine, antidepressants 
(both 14.2%) and others (including antipsychotics and la-
motrigine) (16.4%). A combination therapy was used in alto-
gether 160 patients (45.9%). Whereof 137 patients (39.3%) re-
ceived a combination of 2 agents and 23 patients (6.6%) of 3 
agents (Figure 2). Most combination therapies included anti-
depressants (64.1%), followed by lithium (43.4%), valproate 
(34.5%) and carbamazepine (23.4%). 
The treatment regime differed depending on the type of 
bipolar disorder: patients with the diagnosis of “pure” bipolar 
disorder received mainly monotherapy (bipolar-I 62.7%, bi-
polar-II 56.2%), whereas patients with a history of mixed epi-
sodes or rapid cycling frequently received combination thera-
py (mixed episodes 57.7%, rapid cycling 55.0%). In these pa-
tients, valproate was most commonly used both as mono-
therapy and in combination with other drugs (mixed episodes 
37.7%, rapid cycling 65.0%). 
Antidepressants were mostly used in patients with bipolar-
II-disorder (48.1%). They were frequently applied in combina-
tion with other drugs. Only in “pure” bipolar patients they were 
also used as a monotherapy (bipolar-I-disorder 6.3%, bipo-
lar-II-disorder 11.9%)(Table 1).
Duration of treatment
Concerning the duration of treatment, lithium was applied 
on an average of 7.0 years, carbamazepine for a period of 3.6 
years, valproate 2.7 years and antidepressants 2.6 years. Among 
the antidepressants, TCAs were applied on average for 4.5 years 
and SSRI for a period of about 2.5 years. Except for lithium, the 
duration of treatment was longer when a combination thera-
py with an antidepressant was applied (Table 2, Figure 3). 
Hospitalisation and occupational status
On average, patients were hospitalized 1.2 times within the 
last 24 months. There was no noteworthy difference between 
the different treatment groups with respect to hospitaliza-
tion. Patients treated with valproate or lithium were hospital-
ized about 1.2 times, patients treated with carbamazepine 1.4 
times, and patients treated with other drugs on average 1.3 
times. Those treated with antidepressants had the lowest hos-
pitalization rate of once during the last two years.
About every other patients (n=172; 49.2%) was able to re-
main on a job. The mean working time was 31.7 hours per 
week. Again, there were no significant differences between the 
various treatment groups with respect to this variable. With 
an occupation rate of 56.2% and an average working time of 
33.1 hours/week, patients treated with antidepressants were 
slightly outperforming the other treatment groups regarding 
the status of occupation. 
Combination of 
3 agents 6.6%
Monotherapy
54.3%
Combination of
2 agents 39.3%
Figure 2. Current number of medications. 
Table 1. Quantities (percentages) of types of medication used in the respective subgroups
“Pure” bipolar-I “Pure” bipolar-II Mixed episode Rapid cycling
Combination without antidepressant 20.0 07.3 28.9 15.0
Combination with antidepressant 17.5 36.2 28.9 40.0
Antidepressant MT 06.3 11.9 0 0
Carabamazepine MT 08.8 06.8 08.9 0
Lithium MT 21.3 13.0 15.6 10.0
Valproate MT 17.5 14.1 13.3 25.0
Combination without valproate 26.3 31.3 33.3 15.0
Combination with valproate 11.3 12.4 24.4 40.0
Others (incl. antipsychotics) 08.8 10.7 04.4 10.0
MT: monotherapy
Table 2. Mean durations of treatment (standard deviation)
Medication
Duration of treatment
in years (standard deviation)
Valproate 2.7 (2.5)  
Lithium 7.0 (6.5)
Carbamazepine 3.6 (3.0)
Antidepressants 2.6 (3.0)
TCA 4.5 (4.1)
SSRI 2.3 (2.4)A Quante et al. 
   www.psychiatryinvestigation.org  159
Of the patients treated with valproate, 48.1% were able to 
work for an average of 30.9 hours, whereas only 45.7% of the 
patients treated with lithium and 46.9% of the patients treat-
ed with carbamazepine were employed (mean working time 
30.8 hours/week for lithium and 32.5 hours for carbamaze-
pine treatment). Only 39.7% of the patients treated with oth-
er drugs (especially antipsychotics) were able to hold a job 
(mean working time 31.9 hours/week). 
Acceptance of medication
To evaluate the acceptance of medication, a scale of four 
items was used (1=very good, 2=good, 3=bad, 4=no accep-
tance). Altogether, the acceptance was “good” (1.89). Two hun-
dreds ninty four patients (84.2%) were satisfied with their me-
dication. 
Two hundreds four patients (58.4%) rated the acceptance 
of their medication as being “good”, 90 patients (25.8%) even 
rated it as being “very good”. Only 49 patients (14.1%) were 
not content with their current medication, 13.5% had a “bad” 
acceptance of their medication, and 0.6% did not accept the 
medication at all. In 1.7% of cases data were missing. Howev-
er, there were no differences between the medication groups 
in this matter (Figure 4). 
Life satisfaction
To evaluate life satisfaction, a scale with 6 numeric items ac-
cording to the German school grade system was used (1=very 
good, 2=good, 3=satisfactory, 4=fair, 5=poor, 6=“unsatisfy-
ing). Missing data were within 0.6% of cases.
Overall, patients evaluated their life satisfaction between 
“good” and “satisfactory” (mean 2.69). Half of the patients (n= 
171; 49.1%) rated their satisfaction as being “good” or “very 
good”, whereas 113 patients (32.3%) rated “satisfactory” and 43 
patients (12.4%) “fair” . Only 19 patients (5.6%) were not content, 
which was mirrored in their ratings of “poor” or “unsatisfying”. 
Differentiated life satisfaction between the medication sta-
tuses, there were no significant differences between all medi-
cation groups. However, patients on a monotherapy with lith-
ium, valproate or antidepressants showed a slight trend to be 
more content with their life than patients treated with a carba-
mazepine monotherapy, a combination therapy, or with oth-
er medications like antipsychotics (Figure 5).
DISCUSSION
To our knowledge, this is the first clinical survey examin-
ing the current treatment status in German outpatients with 
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bipolar disorder. Surprisingly, the majority of patients in this 
study population suffered from bipolar-II-disorder, which is 
quite uncommon. However, in the last years more and more 
clinical investigations put its focus on bipolar disorder, which 
may lead to a higher alertness in diagnosing even hypomanic 
episodes. The majority of outpatients assessed received a phar-
macotherapy as recommended in the guidelines for bipolar dis-
order. However, since guideline recommendations are only he-
sitantly implemented into clinical practice, the reasons for these 
facts should be examined to further improve clinical care for 
this chronically ill population. Contrary to the growing trend, 
the application of atypical antipsychotics was rather low. Pre-
sumably, high costs for atypical antipsychotics and restricted 
budgets of the medical practitioners could be a cause for this 
observation. 
In a study by Baldessarini et al.
24 the current treatment sta-
tus of US bipolar patients was examined: in this cohort, 61.3% 
received antipsychotics, and 76.2% a combination with at least 
2 medications. Only half of our patients were treated with a 
combination of psychopharmacological substances, which is, 
comparable to other data in the literature, quite low and may 
reflect the higher proportion of patients with bipolar-II-dis-
order. 
On the other hand, in comparison to treatment regimes in 
the past, it also reflects and confirms the growing trend for 
combination therapies in bipolar disorder, especially in pa-
tients with a history of rapid cycling and mixed episodes. 
There seem to be no differences in life satisfaction according 
to the treatment statuses. However, in our study population 
some patients receiving a monotherapy with lithium, valpro-
ate, or antidepressant seem to be trendwise more content with 
their life than patients receiving a combination therapy. This 
may indicate better tolerance of monotherapy. 
On the other hand, patients receiving a combination ther-
apy may have more severe and/or more frequent episodes 
which per se may decrease life satisfaction. 
According to the guidelines of bipolar disorder, a mono-
therapy with antidepressants is not recommended.
7,8 In our 
cohort, only a few patients received a monotherapy with an-
tidepressants. Surprisingly, TCA, which have a high switch 
rate, are used more frequently than serotonin reuptake inhibi-
tors. This suggests that quality of care needs further improve-
ments. Antidepressants were the most frequently used sub-
stance class for combination therapy. Importantly, it has to be 
pointed out that, there is some data suggesting that antide-
pressants in bipolar patients do not have positive effects on bi-
polar depression.
11 Thus, the prescription of antidepressants 
in bipolar patients seems to continue being popular despite 
the data being inconsistent and their administration being 
controversial.
Patients with a history of rapid cycling were frequently treat-
ed with valproate either in combination or as a monotherapy. 
This may reflect better effectiveness of valproate in these pa-
tients and supports the conclusions of other studies, that val-
proate, even in combination, may be more effective in pa-
tients with a history of rapid cycling.
25,26 Lithium seems to be 
an apt long term medication; the duration of treatment with 
lithium was on an average of 7 years, whereas the duration of 
treatment with other medications was much shorter. 
The occupational status of 49.2% in our study population is 
comparable with other data in the literature. Besides the dis-
ease age, gender and family life e.g., child care may also play a 
confounding role regarding the unemployment statistics. 
There were no significant differences between the patients 
when grouped according to their medications. Still, antide-
pressants outperformed the other substances slightly as we 
observed a trend for higher employment rates and more work-
ing hours in patients treated with them. Despite of the con-
troversial discussion concerning antidepressants in bipolar 
disorder, they might have putative positive effects in long-term 
treatment. In a study of Altshuler et al.
27 a depressive relapse 
of patients with bipolar disorder was significantly associated 
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with discontinuation of antidepressants after remission, which 
also may indicate the importance of antidepressants in this 
disorder. 
To our knowledge, this is the first study to collect data on 
the effects of medication on occupational status in bipolar pa-
tients. Further studies focusing on this are strongly needed be-
cause improvements in the ability to work will putatively lead 
to better life satisfaction and lower costs for the health care 
system. Contrary to the low adherence rates in bipolar patients 
in other studies, the acceptance of the medication in our pop-
ulation was very good. Importantly though, it has to be dif-
ferentiated between the concepts of acceptance and adher-
ence, the latter of which we did not actually assess explicitly.
In other studies, adherence is measured by other instru-
ments, e.g., by intensity (with the medication possession ration) 
and treatment duration.
20 Adherence measurements should 
be implemented for further surveys and also should be cor-
related with the current medication status. 
Concerning life satisfaction, most of the patients were con-
tented or satisfied. As a limiting factor, we did not use stan-
dardized measurements for QOL like the World Health Or-
ganisation’s Quality of Life Assessment Instrument-Bref (WHO-
QOF-Bref).
28 
We also did not implement a questionnaire for the current 
symptoms, like the Symptoms Checklist-90,
29 to correlate it 
with the QOL and the treatment status. It is well documented 
that bipolar disorder greatly affects QOL. Moreover, even pa-
tients who are symptom free or in a stable euthymic state can 
have lowered QOL.
22 In further studies, such measurements 
should be implemented, especially to make the results inter-
nationally comparable. 
Acknowledgments
The study was developed and managed by Sanofi-Aventis, Germany. 
The statistical analysis was performed by “Pharma Direkt GmbH”.
REFERENCES
1. Angst J, Sellaro R. Historical perspectives and natural history of bipo-
lar disorder. Biol Psychiatry 2000;48:445-457.
2. Sharma R, Markar HR. Mortality in affective disorder. J Affect Disord 
1994;31:91-96.
3. Tohen M, Hennen J, Zarate CM Jr, Baldessarini RJ, Strakowski SM, 
Stoll AL, et al. Two-year syndromal and functional recovery in 219 
cases of first-episode major affective disorder with psychotic features. 
Am J Psychiatry 2000;157:220-228.
4. Kupka RW, Altshuler LL, Nolen WA, Suppes T, Luckenbaugh DA, Le-
verich GS, et al. Three times more days depressed than manic or hypo-
manic in both bipolar I and bipolar II disorder. Bipolar Disord 2007; 
9:531-535.
5. Judd LL, Akiskal HS, Schettler PJ, Endicott J, Maser J, Solomon DA, et 
al. The long-term natural history of the weekly symptomatic status of 
bipolar I disorder. Arch Gen Psychiatry 2002;59:530-537.
6. The World Health Organisation. The World Health Report 2000-He-
alth Systems: Improving Performance. [Homepage: http://www.who.
int/whr/2000/en/]. 2000. 
7. Yatham LN, Kennedy SH, O’Donovan C, Parikh SV, MacQueen G, 
McIntyre RS, et al. Canadian Network for Mood and Anxiety Treatments 
(CANMAT) guidelines for the management of patients with bipolar 
disorder: update 2007. Bipolar Disord 2006;8:721-739.
8.  Practice guideline for the treatment of patients with bipolar disorder 
(revision). Am J Psychiatry 2002;159:1-50.
9. Baldessarini RJ, Perry R, Pike J. Factors associated with treatment non-
adherence among US bipolar disorder patients. Hum Psychopharma-
col 2008;23:95-105.
10.   Miller DS, Yatham LN, Lam RW. Comparative efficacy of typical and 
atypical antipsychotics as add-on therapy to mood stabilizers in the 
treatment of acute mania. J Clin Psychiatry 2001;62:975-980.
11.   Sachs GS, Nierenberg AA, Calabrese JR, Marangell LB, Wisniewski 
SR, Gyulai L, et al. Effectiveness of adjunctive antidepressant treatment 
for bipolar depression. N Engl J Med 2007;356:1711-1722.
12.   Leverich GS, Altshuler LL, Frye MA, Suppes T, McElroy SL, Keck PE 
Jr, et al. Risk of switch in mood polarity to hypomania or mania in pa-
tients with bipolar depression during acute and continuation trials of 
venlafaxine, sertraline, and bupropion as adjuncts to mood stabilizers. 
Am J Psychiatry 2006;163:232-239.
13.   Baldessarini RJ. Enhancing treatment with psychotropic medicines. 
Bull Menninger Clin 1994;58:224-241.
14.   Keck PE Jr, McElroy SL, Strakowski SM, Bourne ML, West SA. Com-
pliance with maintenance treatment in bipolar disorder. Psychopharma-
col Bull 1997;33:87-91.
15.   Sajatovic M, Valenstein M, Blow FC, Ganoczy D, Ignacio RV. Treatment 
adherence with antipsychotic medications in bipolar disorder. Bipolar 
Disord 2006;8:232-241.
16.   Lin D, Mok H, Yatham LN. Polytherapy in bipolar disorder. CNS Drugs 
2006;20:29-42.
17.   Baethge C, Baldessarini RJ, Mathiske-Schmidt K, Hennen J, Berghofer 
A, Muller-Oerlinghausen B, et al. Long-term combination therapy ver-
sus monotherapy with lithium and carbamazepine in 46 bipolar I pa-
tients. J Clin Psychiatry 2005;66:174-182.
18.   Busch AB, Ling D, Frank RG, Greenfield SF. Changes in the quality of 
care for bipolar I disorder during the 1990s. Psychiatr Serv 2007;58:27-33.
19.   Eaddy M, Grogg A, Locklear J. Assessment of compliance with antipsy-
chotic treatment and resource utilization in a Medicaid population. Clin 
Ther 2005;27:263-272.
20.   Gianfrancesco FD, Sajatovic M, Rajagopalan K, Wang RH. Antipsy-
chotic treatment adherence and associated mental health care use among 
individuals with bipolar disorder. Clin Ther 2008;30:1358-1374.
21.   Darling CA, Olmstead SB, Lund VE, Fairclough JF. Bipolar disorder: 
medication adherence and life contentment. Arch Psychiatr Nurs 2008; 
22:113-126.
22.   Goossens PJ, Hartong EG, Knoppert-van der Klein EA, van AT. Self-
reported psychopathological symptoms and quality of life in outpatients 
with bipolar disorder. Perspect Psychiatr Care 2008;44:275-284.
23.   Yen CF, Cheng CP, Huang CF, Yen JY, Ko CH, Chen CS. Quality of life 
and its association with insight, adverse effects of medication and use 
of atypical antipsychotics in patients with bipolar disorder and schizo-
phrenia in remission. Bipolar Disord 2008;10:617-624.
24.   Baldessarini R, Henk H, Sklar A, Chang J, Leahy L. Psychotropic med-
ications for patients with bipolar disorder in the United States: poly-
therapy and adherence. Psychiatr Serv 2008;59:1175-1183.
25.   Freeman TW, Clothier JL, Pazzaglia P, Lesem MD, Swann AC. A dou-
ble-blind comparison of valproate and lithium in the treatment of acute 
mania. Am J Psychiatry 1992;149:108-111.
26.   Calabrese JR, Rapport DJ, Kimmel SE, Reece B, Woyshville MJ. Rapid 
cycling bipolar disorder and its treatment with valproate. Can J Psychi-
atry 1993;38:S57-S61.
27.   Altshuler L, Suppes T, Black D, Nolen WA, Keck PE, Frye MA, et al. 
Impact of antidepressant discontinuation after acute bipolar depres-162  Psychiatry Investig 2010;7:155-162
Psychopharmacological Treatment Status in Bipolar Disorder
sion remission on rates of depressive relapse at 1-year follow-up. Amer-
ican Journal of Psychiatry 2003;160:1252-1262.
28. The World Health Organization Quality of Life Assessment (WHO-
QOL): development and general psychometric properties. Soc Sci Med 
1998;46:1569-1585.
29.   Ardinell WA, Ettema JH. Symptom Checklist 90; SCL-90. Amsterdam: 
Harcourt Assessment B V;2005.